Wall Street Zen Upgrades Precision BioSciences (NASDAQ:DTIL) to Hold

Precision BioSciences (NASDAQ:DTIL) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a report on Tuesday, November 3rd. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.25.

Precision BioSciences Stock Performance

NASDAQ DTIL opened at $10.60 on Friday. The firm has a market cap of $296.16 million, a price-to-earnings ratio of -8.55 and a beta of 1.34. The company has a quick ratio of 10.47, a current ratio of 10.47 and a debt-to-equity ratio of 0.43. The business has a 50-day moving average price of $6.90 and a 200-day moving average price of $6.62. Precision BioSciences has a twelve month low of $3.53 and a twelve month high of $11.29.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.57. Precision BioSciences had a negative return on equity of 56.69% and a negative net margin of 96.73%. The company had revenue of $1.25 million for the quarter, compared to the consensus estimate of $1.38 million. As a group, equities research analysts predict that Precision BioSciences will post -2.60 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in shares of Precision BioSciences by 4,217.9% in the third quarter. Russell Investments Group Ltd. now owns 82,818 shares of the company’s stock worth $518,000 after buying an additional 80,900 shares in the last quarter. Engineers Gate Manager LP bought a new position in Precision BioSciences during the second quarter valued at approximately $164,000. Squarepoint Ops LLC grew its holdings in Precision BioSciences by 212.7% during the 2nd quarter. Squarepoint Ops LLC now owns 137,106 shares of the company’s stock valued at $1,078,000 after buying an additional 93,258 shares in the last quarter. Corient Private Wealth LP grew its holdings in Precision BioSciences by 70.4% during the 2nd quarter. Corient Private Wealth LP now owns 245,058 shares of the company’s stock valued at $1,926,000 after buying an additional 101,206 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Precision BioSciences during the 2nd quarter valued at approximately $467,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

More Precision BioSciences News

Here are the key news stories impacting Precision BioSciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $2.01 from a loss of $3.47, and its Q4 2026 estimate to a loss of $0.72 from a loss of $1.20. The less severe projected losses could support sentiment about near-term finances. The analyst retained a Buy rating. Precision BioSciences analyst estimates
• Neutral Sentiment: Wall Street Zen upgraded Precision BioSciences to Hold. This is a more favorable rating than a Sell, but it does not signal a bullish outlook. Precision BioSciences upgraded to Hold
• Negative Sentiment: HC Wainwright lowered EPS estimates across 2027–2029, including its FY2027 estimate to a loss of $1.67 from $1.55 and FY2028 to a loss of $0.85 from $0.75. Its FY2029 loss estimate widened to $1.04 from $0.95, while its FY2030 profit estimate fell to $1.13 from $1.24. These revisions suggest a weaker longer-term earnings outlook, despite the Buy rating. Precision BioSciences analyst estimates

Precision BioSciences Company Profile

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.